Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 1
1988 4
1989 2
1990 1
1991 4
1992 2
1993 6
1994 8
1995 8
1996 4
1997 6
1998 10
1999 17
2000 12
2001 16
2002 11
2003 21
2004 25
2005 15
2006 18
2007 23
2008 25
2009 24
2010 21
2011 29
2012 34
2013 31
2014 22
2015 22
2016 22
2017 17
2018 14
2019 23
2020 28
2021 21
2022 23
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Arase Y, Kagawa T, Tanaka A. Arase Y, et al. Hepatology. 2020 Jul;72(1):360-361. doi: 10.1002/hep.31084. Hepatology. 2020. PMID: 31863598 Free PMC article. No abstract available.
Reply.
Arase Y, Kagawa T. Arase Y, et al. Hepatology. 2020 Mar;71(3):1132-1133. doi: 10.1002/hep.30999. Epub 2020 Mar 4. Hepatology. 2020. PMID: 31628871 Free PMC article. No abstract available.
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S. Fukushima T, et al. Among authors: arase y. Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 10.1093/oncolo/oyad090. Oncologist. 2023. PMID: 37023703 Free PMC article.
Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.
Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Yamaoka K, et al. Among authors: arase y. Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101799. doi: 10.1016/j.clinre.2021.101799. Epub 2021 Sep 7. Clin Res Hepatol Gastroenterol. 2022. PMID: 34500120 Free article.
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors.
Akuta N, Kawamura Y, Fujiyama S, Nakamichi K, Saegusa E, Ogura H, Kato M, Doi E, Inoue N, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Suzuki Y, Kumada H, Suzuki F. Akuta N, et al. Among authors: arase y. Hepatol Res. 2023 Jul;53(7):607-617. doi: 10.1111/hepr.13897. Epub 2023 Mar 17. Hepatol Res. 2023. PMID: 36891614
Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy.
Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Uojima H, et al. Among authors: arase y. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873. doi: 10.1097/MEG.0000000000002581. Epub 2023 Jun 6. Eur J Gastroenterol Hepatol. 2023. PMID: 37395239
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma.
Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Kawamura Y, et al. Among authors: arase y. Cancers (Basel). 2023 Jul 26;15(15):3789. doi: 10.3390/cancers15153789. Cancers (Basel). 2023. PMID: 37568605 Free PMC article.
517 results